ALXB
ALEMS
Market cap3mUSD
, Last price
EUR
Name
DMS Imaging SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Belgium, European Medical Solutions specializes in the creation, advancement, and production of medical imaging equipment for both digital radiography and bone density assessment. Its comprehensive product range includes fluoroscopy (R/F) systems, such as the innovative PLATINUM NEO, designed to significantly enhance R/F workflow, and the reliable OPTIMA dRF. The company further provides devices for bone densitometry and detailed body composition analysis, along with components for dedicated chest and skeletal imaging rooms, like floor and ceiling-mounted tube stands. Other offerings extend to portable radiography units, system upgrade kits, C-ARM solutions for mobile operating theaters, and specialized mammography equipment. The organization, which was originally established as DMS Imaging SA in 1979 and is headquartered in Ixelles, Belgium, officially rebranded to European Medical Solutions in June 2024. It currently operates as a subsidiary of Diagnostic Medical Systems S.A.
Key people
Beatrice De Vos
Chairman of the Board
Thierry Legon
Chief Executive Officer, Director
Francois Meurgey
Marketing & Commercialization, Director
Marie-Claire Beckers
Head of Production
Adrian Caplanusi
Senior Medical Director
Sacha Gogev
Head of Quality Control
Sabine Pirotton
Senior Clinical Project Manager
Albert Vicaire
Secretary of the company
Philippe Degeer
Director - Representative of Meusinvest
Henri De Meyer
Director
Jean-Claude Duchateau
Director
Director
Everard van der Straten
Director · since 2019
Gerd Zettlmeissl
Director
Legal address
Avenue Louise 231
Ixelles 1050
BE
Ixelles 1050
BE
Headquarters
9 AVENUE DU CANAL PHILIPPE LAMOUR
GALLARGUES LE MONTUEUX 30660
FR
GALLARGUES LE MONTUEUX 30660
FR
Previous name
ASIT BioTech SA
Previous name
Biotech Tools SA
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||